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Abstract: The coronavirus nucleocapsid (N) is a structural protein that forms complexes 
with genomic RNA, interacts with the viral membrane protein during virion assembly and 
plays a critical role in enhancing the efficiency of virus transcription and assembly.  
Recent studies have confirmed that N is a multifunctional protein. The aim of this review is 
to highlight the properties and functions of the N protein, with specific reference to (i) the 
topology; (ii) the intracellular localization and (iii) the functions of the protein. 
Keywords: nucleocapsid protein; coronavirus assembly; coronavirus N; intracellular 
localization; protein topology 
 
1. Introduction 
Coronaviruses (CoVs) have a global distribution and infect a variety of human and animal hosts, 
causing illnesses that range from mostly upper respiratory tract infections in humans to gastrointestinal 
tract infections, encephalitis and demyelination in animals; and can be fatal [1,2]. The International 
Committee for Taxonomy of Viruses (ICTV) reports four coronavirus genera, namely Alphacoronaviruses, 
Betacoronaviruses, Gammacoronaviruses and Deltacoronaviruses [3]. CoVs are enveloped  
single-stranded, positive-sense RNA viruses with genomes ranging between 26.2–31.7 kb, the largest 
among known RNA viruses [4]. This large, capped and polyadenylated genome contains seven 
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common coronavirus genes in the following conserved order: 5'-ORF1a-ORF1b-S-ORF3-E-M-N-3' [5]. 
ORF1a/b encompasses two-thirds of the genome and produces a genome-length mRNA (mRNA1) that 
encodes two overlapping viral replicase proteins in the form of polyproteins 1a (pp1a) and pp1ab [6]. 
These polyproteins are formed as a result of a -1 ribosomal frame shift that involves a complex 
pseudoknott RNA structure [7] and are then proteolytically processed by virally encoded proteases into 
mature nonstructural proteins (nsp1 to nsp16), which assemble to form a membrane-associated viral 
replicase-transcriptase complex (RTC) [6,8,9]. The last third of the genome produces subgenomic (sg) 
mRNAs that encode the four structural proteins, spike (S), envelope (E), membrane (M), and 
nucleocapsid (N), as well as a number of accessory proteins [10,11].  
2. Topology of CoV N and RNA Binding 
Amino acid sequence comparisons have shown that CoV N proteins have three distinct and highly 
conserved domains: two structural and independently folded structural regions, namely the N terminal 
domain (NTD/domain 1) and C-terminal domain (CTD/domain 3), which are separated by a 
intrinsically disordered central region (RNA-binding domain/domain 2) (Figure 1); all three domains 
have been shown in different CoVs to bind with viral RNA [12–17]. 
Figure 1. Domain organization of the Severe Acute Respiratory Syndrome human 
coronavirus (SARS-CoV) nucleocapsid protein. IDR (a.a. 1–44; 182–247; 366–422)—
intrinsically disordered regions; NTD (a.a. 45–181)—N terminal domain; LKR (182–247)—
linker region; CTD (248–365)—C-terminal domain. The charged SR rich (striated box) and 
the nuclear localization signal (NLS, solid box) motifs are shown [16,18,19]. 
 
 
The NTD is divergent in both sequence and length. It has been mapped for Infectious Bronchitis Virus 
(IBV)-N to aa 19–162 [20], for Severe Acute Respiratory Syndrome human coronavirus (SARS)-N to  
aa 45–181 [16], and for Mouse hepatitis Virus (MHV)-N to aa 60–197 [18]. The N-termini of these 
three CoVs have been found to associate with the 3' end of the viral RNA genome, possibly through 
electrostatic interactions [21,22]. There are several common characteristics of CoV N protein NTDs, 
including predicted secondary structures such as a central β-sheet platform flanked by α-helices [20], 
with a basic RNA binding groove along the β-platform and an extended β-hairpin. The NTD is 
enriched in aromatic and basic residues and the folded shape resembles a hand with basic fingers that 
extend far beyond the protein core, a hydrophobic palm, and an acidic ―wrist‖ [21]. It has been 
proposed that the flexible, positively charged finger-like β-hairpin extension in the NTD of both IBV 
and SARS-CoV N protein is able to grasp RNA by neutralizing its phosphate groups, while the base 
moieties can make contact with exposed aromatic residues from the hydrophobic palm [16,21].  
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More precise mapping of the RNA-binding site locations has been determined for SARS- and IBV-N 
protein. Within the NTD of SARS-CoV-N, positively charged lysine and arginine residues have been 
proposed to bind a 32 nucleotide stem-loop structure located at the 3' end of the SARS-CoV RNA 
genome [16]. Site-directed mutagenesis studies on IBV-N have identified two residues that are critical 
for RNA binding; namely Tyr-94 and Arg-76 [23]. Tyr-94 is located in strand β3 of the four-stranded 
anti-parallel β sheet; Arg-76 is located in the immediate vicinity of Tyr-94, at the base of the extended 
flexible hairpin loop [23]. It is however likely that, since no single mutation totally disrupts RNA 
binding, other aromatic/basic residues at the surface of the NTD contribute to nucleic acid binding by 
creating a broad surface that comes into contact with the viral genomic RNA [23]. The NTD possesses 
some features similar to those of other RNA-binding proteins that form a RNP. For example, the U1A 
spliceosomal protein [24] and the coat protein of MS2 bacteriophage [25] bind viral RNA with 
residues arising from the surface of a four-stranded anti-parallel β sheet. Seemingly, strands β2, β3, 
and the flexible β-hairpin from the IBV N protein could fulfill a comparable role by interacting with 
phosphate groups on the viral RNA [23]. The Arg-76 and Tyr-94 residues in the IBV N protein are 
well conserved across the whole CoV family, and may structurally correspond to the Arg-94 and  
Tyr-122 residues in the SARS-CoV N protein [23], meaning that Arg-94 and Tyr-122 may therefore be 
critical for SARS N-RNA binding.  
The crystal structure of MHV N197 (residues 60–197) adopts a U-shaped β-platform containing 
five short β-strands (arranged β4-β2-β3-β1-β5) across the platform with an extended β2'-β3' hairpin 
similar to NTDs from other CoV N proteins [26]. Interestingly, the crystal structure of the MHV NTD 
shares a similar overall and topology structure with that of SARS-CoV and IBV but varies in its 
potential surface, indicating a possible difference in RNA-binding module [27]. It has been shown that 
N219, an MHV-A59 N domain protein fragment that contains the folded NTD and the immediately 
adjacent intact linker region (LKR; residues 60–219), binds to the TRS in the viral genome body 
(TRS-B) and complementary TRS (cTRS) with high affinity to form a N219-TRS duplex [26]. MHV 
TRS binds across the β-platform of NTD in a defined orientation, with the 5'-end of TRS near β4 and 
the 3'-end of TRS near β5; this N219 binding to single-stranded RNAs—containing the TRS or 
cTRS—uses base stacking interactions between aromatic side chains on the β-platform with a triple 
adenosine motif within the TRS, 5'-gAAUCUAAACU-3' [26]. Furthermore, due to its potent  
helix-destabilizing activity, N219 is able to efficiently melt an RNA duplex between the template TRS 
and nascent cTRS strand into component single strands that may be transiently formed during 
discontinuous transcription of viral sgRNA by the coronaviral replicase complex [26]. Three residues 
on the β-platform have been shown to play key roles in TRS binding and helix destabilization:  
Arg-125 and Tyr-127 on the β3 strand and Tyr-190 on the β5 strand, suggesting that the AAA motif in 
the 3'-end of the TRS is anchored here [18]. These three residues are completely invariant in 
betacoronavirus N proteins and occupy precisely analogous positions on the fold of each NTD, and are 
therefore likely to define similar RNA binding grooves in the closely related SARS NTD [18]. The 
duplex formation and duplex TRS unwinding activity exhibited by N219 therefore implicates MHV 
NTD in template switching during discontinuous sgRNA transcription [28,29]. Moreover, the ability 
of the NTD to melt dsRNA may also play a role in RNA packaging or other steps in the viral life cycle 
where RNA remodeling is needed [26]. For example, mutations that cripple duplex unwinding are 
defective in stimulating CoV replication in BHK-R cells, and are lethal, providing evidence of a 
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critical role for NTD in viral replication [18,26]. CoV N proteins have also been recognized as RNA 
chaperones [30,31], which, as part of their chaperone activities, anneal nucleic acids, and so RNA 
duplex destabilization activity may be important in CoV N NTDs role in assisting viral RNA in 
reaching its functional three-dimentional structure. Viral nucleocapsid and replication accessory 
proteins from other viruses have also been shown to function as RNA chaperones and facilitate helix 
destabilization, for example HIV-1 NCp7 protein [32], and adenovirus DNA binding protein [33]. 
The NTD is separated from the CTD by an intrinsically disordered middle region referred to as the 
linker region (LKR). The charged LKR is also known as the SR-domain because it is rich in serine and 
arginine residues [34], and it is involved in cell signaling [15,35,36]. The flexible LKR is capable of 
direct interaction with RNA under in vitro conditions [37]. Potential phosphorylation sites have been 
mapped to the Ser/Arg-rich portion of the LKR of SARS-CoV N [38–40]. These LKR phosphorylation 
sites are thought to function in binding M protein, heteronuclear ribonucleoprotein (hnRNP-A1) and 
RNA to the N protein with high binding affinity [14,41–43]. There are conflicting reports regarding 
the involvement of the LKR in N protein oligomerization. Some studies has suggested that the LKR is 
directly involved [44] and that through electrostatic effects, hyperphosphorylation of the LKR reduces 
the total positive charge on the SARS-CoV N protein and leads to enhanced oligomerization of  
di-domain constructs [45]. Other studies have, however, reported that the LKR interferes with 
oligomerization when the CTD is present [46] or if the LKR is phosphorylated [38]. Despite almost no 
structural information being available for the LKR, possibly due to its high positive charge and flexible 
nature [47], there is evidence in support of the functional importance of intrinsically disordered regions 
in proteins for modulating transcription, translation, post-translational modifications such as 
phosphorylation, and cell signaling [48]. RNA chaperones often have structural flexibility because the 
RNA-protein recognition process often requires conformational changes in the RNA, the protein or 
both [49]. An interaction between N protein and a subunit of the viral replicase-transcriptase complex, 
namely non-structural protein 3 (nsp3), has been described and key binding determinants localize to 
the LKR [50,51], highlighting the importance of this unstructured region for a number of potential 
interactions, such as viral infectivity [52]. It has also been proposed that nsp3 binding induces a 
conformational change in the LKR, potentially regulating the intracellular localization of N to the site 
of replication [50] and/or other RNA binding functions of N.  
The CTD, which is a hydrophobic, helix-rich terminal, has been mapped for SARS-N to  
aa 248–365 [17], and for IBV-N to aa 219–349 [21,53]. This domain is also referred to as the 
dimerization domain because it contains residues responsible for self-association to form homodimers, 
as well as homo-oligomers through a domain-swapping mechanism [16,17,42,53–57]. Oligomerization 
of N protein is necessary to produce a stable conformation because in its monomeric form, the CTD 
folds into an extended conformation with a large cavity in its center, making it unstable [47].  
Sequence comparison shows that the dimerization domain of the N protein is conserved at least among 
the alpha, beta and gamma groups of CoVs, suggesting a common structural and functional role for 
this domain [47]. The monomer of cSARS-N, a crystalized C-terminal construct of SARS-N that 
contains residues 270–370, comprises five short α-helices, one 310 helix, and two β-strands [47]. The 
general shape of the monomer resembles the letter C, with one edge formed by a β-hairpin extending 
away from the rest of the molecule [47]. This structure is similar to the crystalline structure of another 
SARS N CTD monomer (NP248–365), which consists of eight α-helices and two β-strands [55].  
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The cSARS-N dimer interface is formed largely by insertion of the β-hairpin of one subunit into the 
cavity of the opposite subunit, resulting in the four β-strands of the two subunits forming an  
anti-parallel β-sheet that is superposed by two long alpha helices [47]. Due to the extensive hydrogen 
bond formation between the two hairpins, together with hydrophobic interactions between the beta-sheet 
and the alpha helices, this interface is highly stable [17], and these interactions suggests that the 
dimeric structure may in fact represent the functional unit of the N protein [47]. The crystal structure 
of NP248–365, a SARS-CoV CTD spanning residues 248–365, revealed that the N protein dimer has 
the shape of a rectangular slab in which the four-stranded β-sheet forms one face of the slab and the  
α-helices form the opposite face [55]. Similarly to cSARS N, the dimerization interface of NP248–365 
is composed of four β-strands and six α-helices, with each protomer contributing one β-hairpin and 
helices α5, α6 and α7. The two β-hairpins form a four-stranded intermolecular β-sheet that is stabilized 
through extensive hydrogen bonding. The other part of the dimerization interface is composed of 
helices α5 and α6, where strong hydrophobic interactions involving Trp302, Ile305, Pro310, Phe315 
and Phe316 were observed. The dimer is further stabilized by hydrophobic interactions between the 
longest helix, α7, and the intermolecular β-sheet [55]. Similarly to cSARS-N and NP248–365, a 
nuclear magnetic resonance (NMR) study has reported secondary structural assignments of a SARS N 
protein construct whose dimeric interface also consists of a four-stranded anti-parallel β-sheet and two 
α-helices [17].  
Self-association of the N protein has been observed in many viruses, and is required for the 
formation of the viral capsid which protects the viral genome from extracellular agents [56].  
In addition to the ability of N protein to oligomerize, viral capsid formation also requires RNA-binding 
ability [58]. Studies revealed that SARS-CoV N protein fragments containing the dimerization domain 
(residues 236-384) can bind to a putative packing signal within the viral RNA, with the most likely 
RNA binding site being within the basic region between residues 248–280 [59]. NMR studies then 
showed that the RNA-binding site between residues 248–280 formed part of the complete dimerization 
domain structure [17]. It was not until the crystal structure of SARS N CTD was resolved that the 
molecular basis of RNA-binding activity and organization of the CTD octamer was determined.  
The CTD spanning residues 248–365 (NP248–365) revealed that, due to the presence of the eight 
positively charged lysine and arginine residues, amino acids 248–280 form a positively charged 
groove, one of the most positively charged regions of the N protein [55]. This groove is similar to that 
in IBV-N CTD, except that the positively charged surface area is larger in the SARS-CoV construct 
than in the IBV [20], due in part to the presence of additional negatively charged residues in the IBV  
N protein and in part due to the absence of residues 215–218 from the IBV construct, which contain 
two lysine residue in the SARS-CoV construct [55]. The NP248–365 construct, which contains both 
the charge-rich region (residues 248–280) and dimerization core (residues 281–365) of the 
dimerization domain, is capable of binding to single-stranded RNA (ssRNA), single-stranded DNA 
(ssDNA) and double-stranded DNA (dsDNA), and NP248–365 has stronger nucleic acid-binding 
activity than the NTD [55,57]. The strong electrostatic character of residues 248–280 and the fact that 
both ssRNA, ssDNA and ddDNA bind to NP248–365, strongly indicates that oligonucleotide binding 
is based on non-specific charge interactions between the positively charged protein and the negatively 
charged nucleic acid backbone [55,60]. By keeping the RNA-binding domains in close proximity to 
the CTD, the formation of a large helical nucleocapsid core is therefore possible [47]. Association of 
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the N protein dimers is necessary for further assembly of the core. The full-length dimeric N protein 
has a tendancy to form tetramers and higher molecular weight oligomers in vitro [54], and a 
serine/arginine-rich motif (residues 184–196) has been shown to be important for N protein 
oligomerization [44]. Two dimers arrange themselves into a butterfly-shaped tetramer, while two 
butterfly-shaped tetramers unite to form an octamer in the asymmetric unit of the CTD crystal [55].  
The octamer is held together through hydrophobic interactions and hydrophilic contacts among the 
four dimers, and networks of inter-dimer hydrogen bonds further help stabilize the octamer [55]. 
Crystallography studies have demonstrated that CoV-SARS CTD (NP248–365) packs as an octamer 
which stacks to form a helical supercomplex structure with a continuous positively charged surface 
that could potentially allow viral RNA strands to bind and wrap around the helical oligomer structure 
through electrostatic interactions [55]. The existence of transient self-association between dimers in 
solution was confirmed using a disulphide trapping technique, and it was shown that by neutralization 
of excessive charges on the protein, either through environmental charge screening or charge 
modifications, this transient self-association can be regulated [44]. This proposed biophysical mechanism 
whereby electrostatic repulsion between N protein molecules acts as an oligomerization switch has 
implications for understanding how nucleocapsid assembly is then subsequently modulated [44].  
In addition, the CTD 45 residues of the MHV N protein have been shown to be the major determinant 
for interaction with the M protein [61], and so association of the N protein with the M protein may also 
play a role in the assembly of the nucleocapsid core into a progeny virion [47]. 
Oligomerization via the CTD has also been reported in human coronavirus 229E (hCoV-229E) and 
a recent study has shown that the C-terminal tail peptide, an intrinsically disordered domain that flanks 
the CTD, plays an important role in dimer–dimer association [53]. The C-terminal tail interferes with 
oligomerization of the CTD and has an inhibitory effect on viral titer of HCoV-229E; and further 
understanding this mechanism of oligomerization may provide insight into the viral assembly process 
and could identify additional targets for drugs to combat CoVs through the disruption of the N protein 
self-association [53]. The CTD of SARS-N (aa 251–422) is also responsible for stress granule 
localization that occurs as part of an integrated stress response in arsenite-treated HeLa cells [38]. 
Once sequestered in these granules, the N protein can induce host translational shutoff. 
The NTD and the CTD are interspersed by intrinsically disordered regions (IDRs) [19,37]. 
Intrinsically disordered proteins (IDPs) or IDRs lack a tertiary structure and have no fixed 3-dimentional 
shape in the native form. However, IDPs and IDRs play a role in various biological functions including 
DNA, RNA and protein binding with the disordered regions facilitating access to these binding  
sites [62–64].  
In fact, the three IDRs in SARS-N (aa 1–44, 182–247 and 366–422) have all been shown to 
modulate the RND-binding activity of the NTD and CTD [19,37]. Moreover, both the middle and  
C-terminal IDRs (Figure 1) have been implicated in the oligomerization of the N protein [44,65], with 
the middle IDR also associated with N protein functionality and N-M interaction [19,39,40,66]. It 
would be interesting to determine whether the presence of three disordered regions in SARS N, 
compared to the one disordered region in HCoV-NL63 N for example, would result in SARS N having 
a higher binding affinity to viral, as well as host cellular proteins. If indeed so, could this then indicate 
a probable basis for the increased pathogenicity of SARS-CoV compared to HCoV-NL63?  
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In order for CoV N proteins to package the viral genome with structural proteins to form 
ribonucleoprotein (RNP) complexes for viral assembly, two key activities are required: the interaction 
between protein and nucleic acid and the ability of the complex to oligomerize [58]. The N proteins of 
SARS-CoV, IBV and MHV have all been shown to perform both these functions. SARS-CoV-N 
protein interacts with RNA at multiple sites, with all three domains having charged regions [55].  
The crystal structures of the NTD and CTD domains of the N protein from SARS-CoV, IBV and MHV 
all share a similar overall and topology structure, which corroborates a conserved mechanism of 
nucleocapsid formation for CoVs [27]. 
Furthermore, despite a lack of significant sequence similarity, the cSARS-N had a similar fold to 
that of the N protein of porcine reproductive and respiratory syndrome virus, a member of 
Arteriviridae family, suggesting an evolutionary link between Coronaviridae and Arteriviridae in 
which the N proteins of both viruses have a common origin [47]. In fact, due to their similar genome 
organization and viral replication mechanisms, the Coronaviridae and Arteriviridae were united to 
form the relatively new order Nidovirales. 
3. Intracellular Localization of the Nucleocapsid Protein  
In virus-infected cells, CoV N proteins can localize to the cytoplasm alone or to the cytoplasm and 
nucleolus [67]. Proteins that are able to localize to the cytoplasm, nucleus and/or nucleolus require 
multiple signals to determine their subcellular localization [68]. CoV N proteins commonly localize in 
the nucleolus, and although nucleolar localization/retention signals (NoRSs) and pathways are not well 
characterized, nucleolar localization usually requires regions in the protein that are rich in Arg residues 
and is likely cell-cycle dependent [34,69,70].  
The N protein of IBV was found to localize in the cytoplasm alone or to co-localize in both the 
cytoplasm and nucleolus [67,68,70]. IBV N protein contains a functional nuclear export signal (NES) 
to traffic N protein to the cytoplasm [68,71], and an 8 amino acid NoRS motif at its NTD and is 
necessary and sufficient for nucleolar retention [68]. It is hypothesized that the localization of IBV-N 
to the nucleolus forms part of a virus strategy to control sgRNA synthesis in both the host cell and 
virus by associating with ribosomal subunits [70] and interacting with nucleolar proteins, nucleolin and 
fibrillarin [72]. Importantly, this interaction is not direct, but mediated through RNA and could 
therefore simply be an artifact of the proteins having RNA-binding domains [73]. Thus, the nucleolar 
localization could simply be due to a high density of the host RNA attracting a viral RNA-binding 
protein. Even so, it has been postulated that the nuclear localization of the N protein may interfere with 
cellular machinery and thus lead to triggering of apoptosis [39]. The localization of N to nucleoli alone 
might be cell cycle dependent, because the number and size of nucleoli differ at different stages of the 
cell cycle: at the beginning of G1 phase, multiple nucleoli can be found, but only single nucleoli can be 
seen at later G1, S and G2 phases [67,74]. It was also found that domain 2 of IBV-N predominantly 
localizes in the nucleus, but when fused with domain 3 (CTD) it localizes to the cytoplasm and thus 
supports the findings of other studies done on IBV-N localization [35,68]. 
The ability for nucleolar localization varies between N proteins of different CoVs. Unlike other 
CoV N proteins, SARS-CoV N protein is mostly distributed to the cytoplasm [34,71,75].  
This cytoplasmic localization is somewhat unexpected because there is at least one NoRS in domain 2 
and eight putative nuclear localization signal (NLS) motifs within domains I and II of the SARS-CoV  
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N protein [35], of which the short lysine-rich sequence (366–381) near the carboxy-terminus is a 
putative bipartite NLS that is unique to SARS-CoV N [71,76]. As a reason for this, it has been 
suggested that signals for nuclear and nucleolar targeting of SARS-CoV N protein are poorly 
accessible to nuclear import machinery due to phosphorylation or conformation restraints [71].  
A cytoplasmic NES may be involved in also over-riding the NLS, resulting in significantly less N 
protein (only 10%) being localized to the nucleolus [35]. Shuttling of N protein from the nucleus to the 
cytoplasm occurs through phosphorylated-dependent binding of SARS-CoV to 14-3-3, with the 
absence/inhibition of this 14-3-3 molecule resulting in increased nuclear localization of SARS-N [38]. 
Also, the deletion of the SR-rich domain contained within the middle region of SARS-N can result in 
dramatic changes in sub-cellular localization of N compared to wild-type N [44]. These results  
indicate that the localization of N protein to the nucleus or nucleolus is not a conserved property  
of Nidovirales [71]. 
4. Functions of the Nucleocapsid  
4.1. Virus Life Cycle 
4.1.1. CoV N and Viral Core Formation 
The primary role of CoV N protein is to package the genomic viral genome into long, flexible, 
helical ribonucleoprotein (RNP) complexes called nucleocapsids or capsids (Table 1). The 
nucleocapsid protects the genome and ensures its timely replication and reliable transmission. The 
filamentous nucleocapsids are 10 to 15 nm in diameter and several 100 nm in length, and these 
macromolecular structures are visible using electron microscopy [77]. Within the nucleocapsid there 
are both N-RNA interactions as well as intermolecular association between disulfide-linked N protein 
multimers [78]. The N-RNA interaction is mediated by binding signals contained within the leader 
RNA sequences [79]. During the virus life cycle, multiple copies of the N protein interact with gRNA 
and sgRNA molecules, indicating a role for N protein in viral transcription and translation [79,80]. The 
basic building block for CoV nucleocapsid formation is a dimeric assembly of N protein [21], and it is 
the CTD of N protein that possesses dimerization function [56]. 
A structural model of CoV proposes that N protein is not only present in the helical nucleocapsid 
but also in the internal spherical/icosahedral core [81]. The internal core consists of N protein, RNA 
and the CTD of M protein. The M protein is the main core shell component and a 16 amino acid 
domain (aa 237–252) on the CTD of M protein binds directly to N protein via an ionic interaction, 
leading to specific genome encapsidation in the budding viral particle [81–83].The N protein therefore 
plays an essential structural role in the CoV virion through a network of interactions with (i) the 
genomic RNA; (ii) M protein and (iii) other N proteins. 
4.1.2. CoV N and Viral Assembly  
Assembly of virus particles is an essential step for a productive viral replication cycle. CoV virions 
contain three envelope proteins, M, E and S, and a viral nucleocapsid, which consists of genomic RNA 
and N protein, within the viral envelope. Assembly of CoV virions not only requires CoV N protein 
dimerization [44,54,56] and association with viral genomic RNA to form RNPs [43,79,81,84–86] but 
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also protein-protein interactions amongst the four structural proteins, as well as a host membrane 
envelope obtained from the site of budding. CoVs acquire their lipid envelope by budding of the 
nucleocapsid through the endoplasmic reticulum (ER)-Golgi intermediate compartment (ERGIC) 
membranes [87,88]. It is believed that the interaction of the nucleocapsid with envelope proteins drives 
the incorporation of the nucleocapsid in enveloped viruses [89], and such protein-protein interactions 
are critical for viral assembly, as has been shown for alphaviruses [90,91].  
N and M proteins are the two major structural proteins in CoV virions [92]. The M protein is 
anchored by its three transmembrane domains to the viral envelope and its large carboxy-terminal tail 
in the virion interior interacts with the nucleocapsid [93]. The nucleocapsid consists of the positive 
strand genomic RNA, mRNA 1, helically encapsidated by N protein monomers, and the N protein 
region that interacts with the C-terminus of the M protein domain seems to be CoV specific.  
The intracellular sites of virus assembly also vary among different viruses [94,95]. 
In MHV, the large carboxy-terminal domain of the M protein interacts with the CTD of the  
N protein [93]. Newly synthesized, unglycosylated M protein interacts with N protein at the ER 
membrane, which is a pre-Golgi compartment that is also the site of MHV budding [96], suggesting 
that the site of interaction overlays with MHV budding sites [93]. The M protein-nucleocapsid 
interaction is thought to be initiated by a direct binding of M protein to genomic RNA that is mediated 
by a 69 nucleotide (nt) packaging signal (ps) present only on the mRNA 1 association [93,97].  
These ps is located about 21kb from the 5' end of MHV mRNA 1 [97,98], is necessary and sufficient 
for packaging RNA into MHV particles [99], and it has been suggested that the M protein-ps 
interaction could lead to the association of M protein with N protein, thereby stabilizing the complex 
between M protein and the nucleocapsid [93]. Although the M protein-nucleocapsid interaction could 
theoretically also be initiated by direct binding of N protein to genomic RNA, this is unlikely because 
N protein interacts with all mRNAs [79,93], which makes it difficult to explain how the formation of 
N protein-mRNA 1 RNP complex might lead to specific packaging of genomic RNA, and not sgRNA, 
into virus particles [100]. It has since been conclusively demonstrated that M protein selectively 
interacts with ps-containing RNA in the absence of N protein, indicating that the mechanism of M-ps 
recognition does not require the formation of RNP complex by N protein, and in fact, N protein is not 
required for RNA packaging in that model [100]. MHV M protein was the first example of a viral 
transmembrane protein that could bind to a specific viral RNA element in the absence of any other 
viral structural proteins [100], and a proposed model for RNA packaging in MHV suggests that once 
M protein accumulates and oligomerizes in the intermediate compartment between the ER and Golgi 
complex, M protein binds to ps-mRNA 1, and only thereafter does N protein associated with mRNA 1 
interact with oligomerized M protein [100]. Although N protein appears to be dispensable for MHV 
RNA packaging, N-M interaction might be important in compensating for viral envelope defects that 
occur due to M protein mutation. The M protein carboxy terminus is extremely sensitive to mutations, 
and removal of even only the last two amino acid residues from the tail of the M protein appears to be 
lethal [83]. Interestingly, N protein becomes mutated in its CTD, and these changes then compensate 
for the loss of the two M protein residues, either by increasing the affinity of an adjacent interaction or 
by providing a new contact point between N and M to stabilize the virion [83]. 
For the porcine transmissible gastroenteritis coronavirus (TGEV), an interaction between the 
carboxy terminus of M and nucleocapsid has been mapped to residues 233–257 of the TGEV M 
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protein [82]. This segment corresponds to residues 201–224 of the MHV M protein [83], which 
overlaps with only one of the critical residues identified in the MHV M protein [61]. This region of the 
two M proteins is, however, poorly conserved and the apparent disagreement between the TGEV and 
MHV results may relate to differences in the respective folds of the M proteins, or differences in how 
these residues influence those folds [61].  
SARS-CoV is markedly different from other members of the Coronaviridae family in the sense that 
there is only 20%–30% amino acid identity with other known CoVs, with both the N and M proteins 
having low sequence homology [76,101]. One might therefore expect that there could be differences in 
the mechanism of viral assembly. A mammalian two-hybrid system, which is performed in vivo so that 
viral proteins will adopt their native state and therefore be more likely to interact in a biologically 
accurate manner [102], confirmed that N-M protein interactions occur in vivo [66]. Moreover, this 
study identified a stretch of amino acids (168–208) in the middle of the N gene that may be critical for 
N-M protein interaction [66]. This stretch of amino acids spans the LKR and dimerization domain in the 
CTD, suggesting that this region may be essential in maintaining correct N protein conformation for both 
self-association and N-M protein interaction [66]. Despite SARS-CoV having the closest genetic 
resemblance to MHV, the M proteins of these viruses bind to different domains on the N protein. 
4.1.3. CoV N and Virus Budding/Envelope Formation 
CoVs assemble and bud intracellularly at the ER-Golgi complex [96,103], and association of the 
nucleocapsid with this organelle may reflect a role in virus budding. The formation of the virion 
envelope requires expression of only M- and E-protein, and not N protein, as has been observed for 
MHV [104], IBV [105], TGEV [106], and BCoV [107]. It was recently noted however, that these 
studies all used vaccinia-based expression systems, where overexpression of viral membrane proteins 
may lead to release in microvesicles, complicating the interpretation of virus-like particle (VLP) 
experiments [108]. Subsequent experiments using transient transfection to express the proteins from 
plasmids have shown that, at least for MHV [109], SARS-CoV [110] and IBV [111], the presence of  
N protein can greatly increase VLP yield. Therefore, while N protein is not necessarily required for 
envelope formation, N protein plays an important role in forming a complete virion [108]. 
4.1.4. Genomic mRNA Replication/Genomic RNA Synthesis 
N protein binds to both full-length genomic RNA (gRNA) as well as all six sgRNAs but displays an 
increased affinity for gRNA [112]. The gRNA functions as a template for the viral RNA-dependent 
RNA polymerase as well as a message for translation [52]. During infection, gRNA is initially 
transcribed by an early polymerase activity into a genome-sized negative-stranded RNA [113] and 
then a late polymerase activity transcribes the negative-stranded RNA into a full length gRNA that is 
bound to polysomes [113] and detected in nucleocapsid structures [114]. Numerous studies have 
demonstrated that N protein is required for optimal CoV replication [31,115–121]. The participation of 
N protein in an early event in RNA synthesis is implied by at least two things: firstly MHV- and 
SARS-CoV N protein colocalize intracellularly with replicase components at early stages of  
infection [122–125]; and secondly, stimulation of gRNA infection is dependent upon N protein 
translation [52,126].  
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A more clearly defined role for N protein in gRNA synthesis was delineated when an interaction 
between the SR region of the MHV N protein and a region in the amino terminal segment of the nsp3 
subunit of the viral replicase was discovered [51,52]. The N-nsp3 interaction has been specifically 
mapped to the ubiquitin-like domain (Ubl1) of nsp3, an essential domain to the virus [127].  
Moreover, it was also shown that this N-nsp3 interaction is required for N protein to promote optimal 
infectivity of gRNA [52]. It was proposed that the formation of an initiation complex at the 3' end of 
the genome requires N protein to tether gRNA to the newly translated replicase via its interaction with 
nsp3 [52,127]. Considering that the start of negative–strand synthesis is the first step in both genomic 
replication and transcription [128,129], it is likely that this N-nsp3 interaction is important in both of 
these RNA-synthetic processes [52]. The role of N protein in MHV gRNA synthesis may not 
necessarily be limited to early time points of infection as it has also been proposed that N protein 
sustains ongoing transcription throughout the course of infection [31,130]. The role of CoV N protein 
in RNA synthesis remains controversial as N protein is not essential for TGEV RNA replication but 
rather for efficient transcription [31].  
4.2. Cellular Response 
4.2.1. Chaperone Activity  
RNA chaperone proteins assist the proper folding of nucleic acids [131,132]. Chaperone activity 
has been postulated as a general activity of all CoV N proteins, and has been demonstrated for TGEV- 
and SARS-CoV N proteins [30]. It has been proposed that amino acids 117–268 in the central 
disordered domain (the LKR domain) of the TGEV N protein has chaperone activity [31], and that this 
region facilitates template switching in vitro by decreasing the energy barrier needed to dissociate the 
nascent minus RNA chain from the gRNA template during discontinuous RNA transcription [30,31]. 
This facilitation of template switching is required for efficient transcription and may explain how the 
presence of N protein therefore increases RNA synthesis. 
4.2.2. Cell Cycle Regulation 
Deregulation of the cell cycle is a common strategy adopted by many RNA (and DNA) viruses 
aimed at exploiting host cell machinery in order to create a more favorable environment for their 
survival. One of the MHV nonstructural proteins, p28, induces G0/G1 cell cycle arrest by inhibiting 
hyperphosphorylation of retinoblastoma protein (Rb), a step which is necessary for cell cycle 
progression through late G1 into the S phase [133–135]. A model was proposed whereby expressed 
cytoplasmic p28 induces stabilization of p53, and accumulation of p53 causes transcriptional 
upregulation of p21, a cyclin-dependent kinase (CDK) inhibitor, leading to suppression of cyclin E/CDK 
2 activities, and the resulting reduction in G1 cyclin-CDK complexes and CDK activities ultimately 
inhibits Rb hyperphosphorylation [133]. Certain herpes simplex virus gene products [136,137], 
cytomegalovirus gene products [138,139], and Zta of Epstein-Barr virus [140] have similarly also been 
shown to arrest cell cycle progression at the G1 phase. IBV infection also perturbs cell cycle 
progression and arrests cells in the S and G2/M phases, and this occurs partly through the interaction of 
IBV nsp3 and DNA polymerase delta [141]. 
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The N protein of SARS-CoV also modulates the host cell cycle by regulating cyclin-CDK activity 
such that S phase progression is halted. The N protein bears a signature cyclin box-binding region (RXL 
motif), can be phosphorylated by CDK and is therefore a substrate for the cyclin-CDK complex [39].  
N protein has been shown to have an inhibitory effect on S phase cyclins CDK4 and to a lesser extent 
CDK6 [39]. The inhibition of kinases means that Rb remains hypophosphorylated and cannot release 
E2F1, and the transcription of S phase genes is halted [135]. Similarly to MHV p28, SARS-CoV N 
protein also inhibits CDK2 activity, meaning that by blocking the activity of both G1 and S phase 
cyclins, N protein doubly ensures the blockage of S phase progression [39]. N protein mediated 
inhibition of CDK activity; leading to inhibition of Rb phosphorylation, is independent of CDK 
inhibitors (CDKIs) such as p21, and so it has been suggested that the N protein mimics the role of 
CDKIs by acting as a competitive inhibitor to CDK4 and CDK2 [39]. The ability of N protein to 
inhibit CDK4 activity was dependent on the RXL motif, whereas its ability to inhibit CDK2 requires at 
least two mechanisms: the CDK phosphorylation motif and dependence on host cell signaling 
pathways [39]. It has been postulated that, p28-mediated (MHV) and N protein-mediated (SARS) 
blocking of the S phase, allows these virus enough time to utilize the cellular raw materials that have 
been synthesized ahead of the S phase, for replication of its genome, as well as for assembly and 
budding of progeny particles [142]. These studies provide evidence that even within the CoV family, 
different proteins can deregulate the cell cycle and that those proteins, in the case of SARS-N protein, 
can employ multiple mechanisms to achieve this.  
4.2.3. Cell Stress Responses—Host Translational Shutoff 
In response to environmental stress, eukaryotic cells reprogram their mRNA metabolism to adapt to 
stress-induced damage. Translationally stalled mRNAs together with a number of translational 
initiation factors and RNA-binding proteins are selectively deposited in cytoplasmic stress granules 
(SGs) [143]. CoVs, like many other viruses, induce host translational shutoff, while maintaining 
synthesis of their own gene products, as a means to interfere with cellular defense mechanisms [144]. 
MHV-induces a host translational shutoff that is reminiscent of a cellular stress response; SGs appear, 
numerous mRNAs including protein translation-related factors are downregulated and levels of 
phosphorylated translation initiation factors increase [145]. It is important to remember, though that 
this translational shutoff could also simply be the host cell’s response to the infection. 
In SARS-infected HeLa cells that are exposed to arsenite treatment, N protein translocates to 
cytoplasmic SGs where it colocalizes with poly(A)-binding protein 1 (PARB) and transiently 
expressed TIA-1 [38], both of which are components of SGs [143]. This localization and pattern was 
enhanced when the protein was hypophosphorylated (NΔRS), perhaps because NΔRS induced larger 
ribonucleoprotein (RNP) complex formation [38]. The sequestration of N protein in SGs possibly 
indicates a role in translational suppression. The nucleocapsid protein of both porcine and respiratory 
syndrome and rubella virus also interact with PARB, which promotes protein synthesis by circularizing 
mRNAs, and inhibit host protein synthesis by sequestration of PARB through a stoichiometric 
mechanism [146,147]. It has been proposed that, at least in the rubella virus, that N-dependent inhibition 
of translation via PARB binding may facilitate the switch from viral translation to packaging RNA into 
nucleocapsids [146]. More specifically, binding of the capsid to PARB late in the virus cycle, when the 
levels of newly synthesized genomes and viral proteins are high, and there is little need for additional 
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replicase components, could prevent recruitment of ribosomes to the nascent 40S RNA. This scenario 
would favour packaging of the 40S genomic RNA into nucleocapsids [146]. Considering that SARS-N 
and MHV-N protein has been shown to interact with the PARB hnRNP-A1 [41,148], it is possible that 
the N-PARB interaction also acts as a switch that redirects viral activity from RNA synthesis to 
nucleocapsid formation. 
The translational suppressive effect of the N protein could also be through its CTD interaction with 
elongation factor 1α (EF1α), a major translational factor in mammalian cells [75]. N protein of SARS-CoV 
binds directly to and induces aggregation of EF1α, resulting in inhibition of protein translation [75]. 
Moreover, EF1α is a multifunctional protein and has unconventional functions related to its association 
with the cytoskeleton, including interaction with filamentous (F) actin, promotion of F actin bundling 
and formation of a contractile ring during cytokinesis [149–152]. N-EF1α therefore blocks  
EF1α–mediated F actin bundling and the formation of the contractile ring, leading to the formation of 
multinucleated cells by inhibiting cytokinesis [75]. Multinucleated syncytia of macrophages have been 
observed in late-phase SARS-CoV but not in other CoV-infected patients [153]. The N protein of 
hCoV-229E also binds to EF1α, but with significantly lower affinity than SARS-CoV N, and induces 
multinucleation much more slowly in a substantially smaller fraction of transfected cells [75].  
In addition, N-protein mediated inhibition of cytokinesis leads to inhibition of cell proliferation in 
human peripheral blood lymphocytes (PBLs) [75]. Since actively dividing lymphocytes are a major 
cell target of SARS-CoV [154], SARS-CoV N may decelerate lymphocyte proliferation and therefore 
interfere with immune system function [75]. 
SARS-N protein has also been shown to cause cytoskeletal changes in response to a different type 
of cell stress, namely serum deprivation [155]. N protein induces actin reorganization in COS-1 
monkey kidney cells by down regulating focal adhesion kinase and fibronectin via p38 MAPK 
pathway activation [155].  
4.2.4. Viral Pathogenesis—Immune System Interference 
N protein plays an important role in viral pathogenesis since anti-N monoclonal antibodies protect 
mice from lethal infection of JMHV [156]. Coronaviruses seem to have developed mechanisms to 
overcome the host innate immune response, including the interferon response, a major component of 
innate immunity. SARS-CoV infected cells do not allow production of interferon and so it seems likely 
that SARS-CoV, like many other viruses, has developed mechanisms to subvert the interferon 
response [157]. SARS-CoV N protein is one of three β interferon (IFβ) antagonists, with ORF3b and 
ORF6 being the other two, and inhibition of IFβ synthesis by N protein is due to inhibition of IRF-3 
and NF-kB, two of the transcription factors required for IF gene expression [158]. SARS-CoV  
N protein inhibits the synthesis of type-1 interferon (1FN) and the CTD of N has been shown to be 
critical for antagonism of 1FN induction [159]. This inhibition of the interferon response likely 
contributes to the pathogenesis of SARS-CoV. 
4.2.5. Signal Transduction 
CoV infection is likely to activate a diversity of host cell signal transduction pathways and kinases, 
which would lead to phosphorylation of N protein [160]. N protein phosphorylation would therefore 
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only occur at a relatively late stage of the viral cell cycle and may explain why more phosphorylated  
N protein is incorporated into IBV virions [161]. 
It has been demonstrated that the SARS-CoV N protein can bind to DNA in vitro [55]. Recently, 
the N protein of hCoV-OC43 was shown to interact with the transcription factor nuclear factor-kappa 
B (NF-kappaB) [73]. It was reported that hCoV-OC43 N protein potentiates NF-kB activation as a 
direct result of the ability of the nucleocapsid to bind microRNA miR-9, a negative regulator of  
NF-kB. It was suggested that this previously undescribed interaction between virus and host is a 
potential mechanism of immune evasion in RNA viruses because NF-kB required for IF gene 
expression [73,158].  
Table 1. Summary of the role of coronavirus N protein in the (1) virus life cycle and (2) cellular response. 
1. Virus Life Cycle Function 
1.1. Viral Core Formation 
 Primary role of CoV N is packaging the viral genome into long, 
flexible, helical RNP complexes [77]. 
1.2. Viral Assembly 
 CoV N protein dimerization [44,54,56] and association with viral 
genomic RNA [43,79,82,84–86] is critical for viral assembly. 
 Interaction amongst the viral structural proteins (N, E, S and M), as 
well as a host membrane envelope obtained from the site of 
budding is required for viral assembly [87,88]. 
1.3. Virus Budding/envelope formation 
 Association of CoV N with the ER-Golgi complex plays a role in 
virus budding [96,103]. 
 Presence of N results in increased yields of VLPs and complete 
virion formation [108–111]. 
1.4. Genomic mRNA 
replication/genomic RNA synthesis 
 Intracellular co-localization of N with replicase components is 
required for RNA synthesis [122–125]. 
 Translation of N protein is implicated in stimulation of gRNA 
infection during RNA synthesis [52,126]. 
2. Cellular Response  
2.1. Chaperone activity 
 All CoV N proteins involved in proper folding of nucleic acids by 
RNA chaperone proteins [131,132]. 
2.2. Cell cycle regulation 
 SARS-CoV N modulates the host cell cycle by regulating cyclin-CDK 
activity. Leads to the arrest in progression of S phase [39]. 
2.3. Cell stress responses—host 
translational shutoff 
 SARS-N and MHV-N interact with cellular hnRNP-A1 [41,148], 
which could act as a switch that redirects viral activity from RNA 
synthesis to nucleocapsid formation. 
 Interaction of N protein CTD with elongation factor 1α (EF1α), a 
major translational factor in mammalian cells, can suppress 
translation [75]. 
2.4. Viral pathogenesis—Immune 
system interference 
 N protein plays an important role in viral pathogenesis. Mice infected 
with JMHV protected by anti-N monoclonal antibodies [156]. 
 Synthesis of type-1 interferon (1FN) inhibited by SARS-CoV N [158]. 
 The CTD of N has been shown to be a critical antagonist of 1FN 
induction [159] 
2.5. Signal transduction 
 Activation of host cell signal transduction pathways and kinases 
leads to phosphorylation of N [160]. 
 
NF-kB is also involved in SARS-CoV mediated activation of cyclooxygenase-2 (COX-2), more 
specifically, N protein binds to NF-kB and CCAAT/enhancer binding protein binding sites on the 
COX-2 gene promoter [162]. Activation of COX-2, a proinflammatory factor, by SARS-CoV N protein is 
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a likely cause of lung inflammation in SARS-CoV infected patients [162]. SARS-CoV N protein is also 
known to activate the activator protein 1 (AP1) signal transduction pathway by increasing the amount of 
transcription factors binding to promoter sequences of c-Fos, ATF2, CREB-1, and FosB [163].  
SARS-CoV N protein induces apoptosis of COS-1 monkey kidney cells in the absence of growth 
factor by down-regulating extracellular-signal-regulated kinase (ERK) and up-regulating c-Jun  
N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (MAPK) pathways, with activation 
of p38 MAPK also causing actin reorganization in serum-deprived cells [155]. 
5. Conclusions  
The coronavirus N protein is abundantly produced within infected cells. N has multiple functions, 
including binding to viral RNA to form the ribonucleocapsid and has also been proposed to have roles 
in virus replication, transcription and translation. In host cells, N proteins have been shown to cause 
deregulation of the cell-cycle [70,142], inhibit the production of interferon [158], up-regulate the 
production of COX2 [162], up-regulate the activity of AP1 [163], and induce apoptosis in serum 
deprived cells [155]—of all which may have possible pathological consequences [164]. Several 
excellent reviews on the coronavirus N protein have previously been published [165,166], including 
one on the structure and function of the SARS-CoV N and its interaction with nucleic acids [19]. 
Notwithstanding these reviews, the manner in which coronavirus N proteins carry out its roles during 
the viral life cycle is still not clearly understood. An important piece of missing information lies in the 
difficulty in resolving the atomic structure of the RNP complex, which has been hampered by low 
solubility of the RNP complex and the labile nature of the full-length N protein. In addition, in order to 
determine whether the RNPs from various coronaviruses share a common structural code, the structure 
of different coronavirus RNPs need to be resolved [19].  
Direct intraviral protein-N interactions identified to date include the interaction between N and  
M [61,92,93] and N and nsp3a, a component of the viral replicase [10,52]. Additionally, in MHV-infected 
cells, monoclonal anti-N antibody co-immunoprecipitates both M and S proteins; this N-S interaction 
is not a direct one though. Rather, it is due to the interaction between S and M protein [93], where the 
S protein forms complexes with M protein in the endoplasmic reticulum (ER) [167,168].  
The identification of host proteins targeted by viral proteins during the infection process provides 
important insights into mechanisms of viral protein function [169]. To date, the interaction of N with 
numerous host cell proteins have been identified, including hCypA [170], proteasome subunit p42 [171], 
the B23 phosphoprotein [172,173], Smad3 [174], nRNP-A1 [148], the chemokine CXCL16 [175], 
translation elongation factor-1 alpha [75], cellular pyruvate kinase protein [176], 14-3-3 [39] and 
nucleolin [73,177]. More recently, a study using high-throughput mass spectrometry identified a list of 
cellular proteins that could potentially interact with the IBV N protein [177]. Comparative studies 
between various coronavirus N protein interactions could provide valuable information on host 
specificity and evolution of the interactions between N and host cell proteins. In turn, this may offer 
insight into the development of novel antiviral therapeutics that target interactions between host cell 
proteins and the N protein [177,178]. 
SARS-CoV N protein is extremely antigenic. SARS-CoV infection causes a highly restricted, 
immunoglobulin G-dominated antibody response that is directed most frequently and predominantly at 
the nucleocapsid [179]. DNA vaccines encoding SARS-CoV N protein generate a strong N-specific 
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humoral and T-cell-mediated response and significantly reduce the viral titre of challenging vaccinia 
virus in C57BL/6-vaccinated mice [180]. Importantly though, another study suggests that N does not 
induce virus neutralizing antibody and as a result, provides no protection to infection in hamsters [181]. 
In the diagnosis/screening hCoV-OC43, rabbit poloyclonal antibodies demonstrated greater 
immunoreactivity to the central (LKR) region and CTD than the NTD of N protein in serum samples, 
highlighting that LKR region is a strong candidate for use in the design of diagnostic tools [182]. 
Understanding the role of N in coronavirus infection could lead to the development of novel 
therapeutics that could potentially be used to combat the threat posed by the emerging lethal human 
coronaviruses identified in recent times. 
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